ANTIBODY BOUND TO NOVEL CORONAVIRUS (SARS-COV-2)

To provide a novel antibody that makes it possible to prevent and/or treat infection with COVID-19.SOLUTION: The present invention provides an antibody or an antibody fragment thereof, wherein the antibody has heavy chain CDR1 consisting of a specific amino acid sequence, heavy chain CDR2 consisting...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SHIGA HAZUKI, MATSUKURA SUSUMU, WATANABE SHINYA, HOSHI HIROTAKA, SATO SHIGEKO, IMAI JUNICHI
Format: Patent
Sprache:eng ; jpn
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator SHIGA HAZUKI
MATSUKURA SUSUMU
WATANABE SHINYA
HOSHI HIROTAKA
SATO SHIGEKO
IMAI JUNICHI
description To provide a novel antibody that makes it possible to prevent and/or treat infection with COVID-19.SOLUTION: The present invention provides an antibody or an antibody fragment thereof, wherein the antibody has heavy chain CDR1 consisting of a specific amino acid sequence, heavy chain CDR2 consisting of a specific amino acid sequence, heavy chain CDR3 consisting of a specific amino acid sequence, light chain CDR1 consisting of a specific amino acid sequence, light chain CDR2 consisting of a specific amino acid sequence, and light chain CDR3 consisting of a specific amino acid sequence, and the antibody is bound to the S2 subunit of SARS-CoV-2.SELECTED DRAWING: None 【課題】COVID-19に対する感染予防および/または治療を可能とする新規抗体の提供を課題とする。【解決手段】特定のアミノ酸配列からなる重鎖CDR1、特定のアミノ酸配列からなる重鎖CDR2、特定のアミノ酸配列からなる重鎖CDR3、特定のアミノ酸配列からなる軽鎖CDR1、特定のアミノ酸配列からなる軽鎖CDR2、および、特定のアミノ酸配列からなる軽鎖CDR3を有する抗体であって、SARS-CoV-2のS2サブユニットに結合する、抗体またはその抗体フラグメント。【選択図】なし
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2023061248A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2023061248A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2023061248A3</originalsourceid><addsrcrecordid>eNrjZDBw9AvxdPJ3iVRw8g_1c1EI8Vfw8w9z9VFw9g_y93MM8wwKDVbQCHYMCtZ19g_TNdLkYWBNS8wpTuWF0twMSm6uIc4euqkF-fGpxQWJyal5qSXxXgFGBkbGBmaGRiYWjsZEKQIAY6ImdQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTIBODY BOUND TO NOVEL CORONAVIRUS (SARS-COV-2)</title><source>esp@cenet</source><creator>SHIGA HAZUKI ; MATSUKURA SUSUMU ; WATANABE SHINYA ; HOSHI HIROTAKA ; SATO SHIGEKO ; IMAI JUNICHI</creator><creatorcontrib>SHIGA HAZUKI ; MATSUKURA SUSUMU ; WATANABE SHINYA ; HOSHI HIROTAKA ; SATO SHIGEKO ; IMAI JUNICHI</creatorcontrib><description>To provide a novel antibody that makes it possible to prevent and/or treat infection with COVID-19.SOLUTION: The present invention provides an antibody or an antibody fragment thereof, wherein the antibody has heavy chain CDR1 consisting of a specific amino acid sequence, heavy chain CDR2 consisting of a specific amino acid sequence, heavy chain CDR3 consisting of a specific amino acid sequence, light chain CDR1 consisting of a specific amino acid sequence, light chain CDR2 consisting of a specific amino acid sequence, and light chain CDR3 consisting of a specific amino acid sequence, and the antibody is bound to the S2 subunit of SARS-CoV-2.SELECTED DRAWING: None 【課題】COVID-19に対する感染予防および/または治療を可能とする新規抗体の提供を課題とする。【解決手段】特定のアミノ酸配列からなる重鎖CDR1、特定のアミノ酸配列からなる重鎖CDR2、特定のアミノ酸配列からなる重鎖CDR3、特定のアミノ酸配列からなる軽鎖CDR1、特定のアミノ酸配列からなる軽鎖CDR2、および、特定のアミノ酸配列からなる軽鎖CDR3を有する抗体であって、SARS-CoV-2のS2サブユニットに結合する、抗体またはその抗体フラグメント。【選択図】なし</description><language>eng ; jpn</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE ; FOODS OR FOODSTUFFS ; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT ; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES ; VINEGAR ; WINE</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20230501&amp;DB=EPODOC&amp;CC=JP&amp;NR=2023061248A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20230501&amp;DB=EPODOC&amp;CC=JP&amp;NR=2023061248A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SHIGA HAZUKI</creatorcontrib><creatorcontrib>MATSUKURA SUSUMU</creatorcontrib><creatorcontrib>WATANABE SHINYA</creatorcontrib><creatorcontrib>HOSHI HIROTAKA</creatorcontrib><creatorcontrib>SATO SHIGEKO</creatorcontrib><creatorcontrib>IMAI JUNICHI</creatorcontrib><title>ANTIBODY BOUND TO NOVEL CORONAVIRUS (SARS-COV-2)</title><description>To provide a novel antibody that makes it possible to prevent and/or treat infection with COVID-19.SOLUTION: The present invention provides an antibody or an antibody fragment thereof, wherein the antibody has heavy chain CDR1 consisting of a specific amino acid sequence, heavy chain CDR2 consisting of a specific amino acid sequence, heavy chain CDR3 consisting of a specific amino acid sequence, light chain CDR1 consisting of a specific amino acid sequence, light chain CDR2 consisting of a specific amino acid sequence, and light chain CDR3 consisting of a specific amino acid sequence, and the antibody is bound to the S2 subunit of SARS-CoV-2.SELECTED DRAWING: None 【課題】COVID-19に対する感染予防および/または治療を可能とする新規抗体の提供を課題とする。【解決手段】特定のアミノ酸配列からなる重鎖CDR1、特定のアミノ酸配列からなる重鎖CDR2、特定のアミノ酸配列からなる重鎖CDR3、特定のアミノ酸配列からなる軽鎖CDR1、特定のアミノ酸配列からなる軽鎖CDR2、および、特定のアミノ酸配列からなる軽鎖CDR3を有する抗体であって、SARS-CoV-2のS2サブユニットに結合する、抗体またはその抗体フラグメント。【選択図】なし</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</subject><subject>FOODS OR FOODSTUFFS</subject><subject>FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT</subject><subject>THEIR TREATMENT, NOT COVERED BY OTHER CLASSES</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDBw9AvxdPJ3iVRw8g_1c1EI8Vfw8w9z9VFw9g_y93MM8wwKDVbQCHYMCtZ19g_TNdLkYWBNS8wpTuWF0twMSm6uIc4euqkF-fGpxQWJyal5qSXxXgFGBkbGBmaGRiYWjsZEKQIAY6ImdQ</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>SHIGA HAZUKI</creator><creator>MATSUKURA SUSUMU</creator><creator>WATANABE SHINYA</creator><creator>HOSHI HIROTAKA</creator><creator>SATO SHIGEKO</creator><creator>IMAI JUNICHI</creator><scope>EVB</scope></search><sort><creationdate>20230501</creationdate><title>ANTIBODY BOUND TO NOVEL CORONAVIRUS (SARS-COV-2)</title><author>SHIGA HAZUKI ; MATSUKURA SUSUMU ; WATANABE SHINYA ; HOSHI HIROTAKA ; SATO SHIGEKO ; IMAI JUNICHI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2023061248A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2023</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE</topic><topic>FOODS OR FOODSTUFFS</topic><topic>FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT</topic><topic>THEIR TREATMENT, NOT COVERED BY OTHER CLASSES</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>SHIGA HAZUKI</creatorcontrib><creatorcontrib>MATSUKURA SUSUMU</creatorcontrib><creatorcontrib>WATANABE SHINYA</creatorcontrib><creatorcontrib>HOSHI HIROTAKA</creatorcontrib><creatorcontrib>SATO SHIGEKO</creatorcontrib><creatorcontrib>IMAI JUNICHI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SHIGA HAZUKI</au><au>MATSUKURA SUSUMU</au><au>WATANABE SHINYA</au><au>HOSHI HIROTAKA</au><au>SATO SHIGEKO</au><au>IMAI JUNICHI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTIBODY BOUND TO NOVEL CORONAVIRUS (SARS-COV-2)</title><date>2023-05-01</date><risdate>2023</risdate><abstract>To provide a novel antibody that makes it possible to prevent and/or treat infection with COVID-19.SOLUTION: The present invention provides an antibody or an antibody fragment thereof, wherein the antibody has heavy chain CDR1 consisting of a specific amino acid sequence, heavy chain CDR2 consisting of a specific amino acid sequence, heavy chain CDR3 consisting of a specific amino acid sequence, light chain CDR1 consisting of a specific amino acid sequence, light chain CDR2 consisting of a specific amino acid sequence, and light chain CDR3 consisting of a specific amino acid sequence, and the antibody is bound to the S2 subunit of SARS-CoV-2.SELECTED DRAWING: None 【課題】COVID-19に対する感染予防および/または治療を可能とする新規抗体の提供を課題とする。【解決手段】特定のアミノ酸配列からなる重鎖CDR1、特定のアミノ酸配列からなる重鎖CDR2、特定のアミノ酸配列からなる重鎖CDR3、特定のアミノ酸配列からなる軽鎖CDR1、特定のアミノ酸配列からなる軽鎖CDR2、および、特定のアミノ酸配列からなる軽鎖CDR3を有する抗体であって、SARS-CoV-2のS2サブユニットに結合する、抗体またはその抗体フラグメント。【選択図】なし</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; jpn
recordid cdi_epo_espacenet_JP2023061248A
source esp@cenet
subjects BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
FOODS OR FOODSTUFFS
FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT
THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
VINEGAR
WINE
title ANTIBODY BOUND TO NOVEL CORONAVIRUS (SARS-COV-2)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T08%3A27%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SHIGA%20HAZUKI&rft.date=2023-05-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2023061248A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true